Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Aug 31 2017

• By Mandy Jackson

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment

Related Content

Too Sick For CAR-T? Kite Reports Cerebral Edema Death

May 09 2017

Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan

Jan 12 2017

What's Gilead Getting From Kite For Nearly $12bn?

Aug 29 2017

Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

Aug 29 2017

Trial And Trial: Bracing For Commercialization Of Cell & Gene Therapies

Aug 25 2017

Kite First Off The Blocks For EU CAR-T Filing

Aug 01 2017

Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place

Dec 05 2016

Related Companies

Novartis AG

Kite Pharma, Inc.

Gilead Sciences, Inc.

Roche Holding AG

Bristol Myers Squibb Company

Additional Topics

Approvals Pricing Strategies Reimbursement Market Access Regulation ImmunoOncology Drug Safety Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window